Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Press Releases
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
84.14 CHF   +0.05%
12/01European Court Of Justice Issues Landmark Judgments Regarding Trademark Enforcement In Parallel Imports Of Generic Pharmaceuticals : No Repackaging/Rebranding As The Originator Reference Product
AQ
11/30Transcript : Novartis AG - Special Call
CI
11/30Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société NOVARTIS AG
12/01European Court Of Justice Issues Lan : No Repackaging/Rebranding As The Originator Referen..
AQ
11/24Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study f..
AQ
11/23Novartis : and Medicines for Malaria Venture announce decision to move to Phase 3 study fo..
PU
11/22Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 da..
GL
11/07New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safet..
GL
11/07Sandoz announces further investment in key manufacturing facility in Austria, to suppor..
GL
11/03Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spe..
AQ
11/02Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz
AQ
10/25Novartis : Q3 Earnings Snapshot
AQ
10/25Novartis : Financial Results – Q3 2022
PU
10/25Novartis maintains growth momentum and confirms FY'22 Group guidance
GL
10/24Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful ..
GL
10/24Novartis : Q3 2022 Results Investor presentation
PU
10/14Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PS..
GL
10/13World Sight Day 2022 : Raising awareness on the importance of eye health
PU
10/12Novartis : The FY 2021 Novartis environmental indicators (PDF 0.
PU
10/12Malaria Pipeline Landscape Analysis of 15+ Companies by DelveInsight
AQ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
09/27Monsenso participates in new, large innovation project
AQ
09/27Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten..
AQ
09/22Novartis unveils new focused strategy, underpinned by eight potential multi-billion dol..
GL
09/21Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (f..
GL
09/19Tysabri® (Natalizumab) Litigation Begins
AQ
09/19Sandoz announces further progress on its biosimilar pipeline, with release of positive ..
GL
09/19Sandoz announces further progress on its biosimilar pipeline, with release of positive ..
AQ
09/15Novartis statement regarding competition authority investigation into assertion of a pa..
GL
09/13Biogen Files Sealed Complaint Against Sandoz And Polpharma Biologics Regarding Natalizu..
AQ
09/12Novartis Hematology : Working to help ensure patients are getting the access they need
PU
09/12Novartis : invests in early technical development capabilities for next-generation biother..
PU
09/10Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hi..
AQ
09/10Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hi..
GL
09/09Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, ..
GL
09/05Novartis Hematology : Working to help ensure patients are getting the access they need
PU
09/02Novartis highlights depth of immunology pipeline with novel data at key upcoming intern..
GL
09/01The Sound Of Silence – The Importance Of Knowing What Your Invention Is Not
AQ
09/01Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMe..
GL
08/31Kaiku Health to improve cancer care through partnership with global medicines company
AQ
08/30Novartis presents new data in breast and prostate cancer at ESMO
GL
08/26Novartis looks at spinning out generics unit
AQ
08/25Branaplam : VIBRANT-HD Study Update
PU
08/25Swiss drugmaker Novartis to spin off generics unit Sandoz
AQ
08/25Novartis announces intention to separate Sandoz business to create a standalone company..
GL
08/19Novartis : Download the Novartis 2030 Environmental Sustainability Strategy
PU
08/15Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant..
GL
08/02Australia's Cell and Gene Catalyst moves ahead
AQ
07/29Sandoz & Polpharma Announce FDA And EMA Acceptance Of Applications For Natalizumab Bios..
AQ
07/25Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc..
GL
07/25Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc..
AQ
07/21Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case
AQ
07/21Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyr..
GL
07/21Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyr..
AQ
07/20Novartis : ESG Update - July 20, 2022 (PDF 0.4 MB)
PU
07/19Novartis : Q2 Earnings Snapshot
AQ
07/19Novartis : Interim financial report (PDF 0.5 MB)
PU
07/19Novartis : Download the interactive presentation (PDF 2.9 MB)
PU
07/19Novartis : Financial Results – Q2 2022
PU
07/19Novartis delivers continued strong momentum of key growth brands, progress on strategic..
GL
07/01Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform tha..
AQ
06/30New Phase III data show Novartis tislelizumab significantly extended median overall sur..
GL
06/30Novartis : resumes production and delivery of radioligand therapy medicines ahead of sched..
PU
06/29Federal Circuit Imposes Heightened Standard For Written Description Support Of Negative..
AQ
06/28Federal Court Finds Janssen's Macitentan Combination Therapy Patent Valid
AQ
06/27Sandoz's High Concentration Adalimumab Biosimilar Application Accepted By EMA
AQ
06/27Novartis : New Novartis extension phase data show nearly 80% of RMS patients treated with ..
PU
06/24Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult pati..
GL
06/23Novartis receives European Commission approval for Tabrecta for the treatment of METex1..
AQ
06/22Novartis renews commitment to neglected tropical disease and malaria elimination, inves..
GL
06/22Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication ..
GL
06/22Novartis : receives European Commission approval for Tabrecta® for the treatment of METex1..
PU
06/21Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for furthe..
GL
06/17Novartis : announces Nature Medicine publication of Zolgensma data demonstrating age-appro..
PU
06/17Sandoz Application for proposed biosimilar adalimumab's high concentration formulation ..
GL
06/17Sandoz Application for proposed biosimilar adalimumab's high concentration formulation ..
AQ
06/16New research reveals the critical actions needed to ensure COVID-19-driven surge in vir..
GL
06/12Novartis five-year Kymriah® data show durable remission and long-term survival maintain..
GL
1  2  3  4  5  6  7  8  9  10Next